Abstract
Chemokines are members of a superfamily of small, cytokine-like, chemotactic proteins that have recently been shown to critically regulate leukocyte trafficking. Accumulating evidence indicates that the chronically relapsing inflammatory skin disease psoriasis represents a T cell-mediated disease. Thus, the understanding of the underlying mechanisms of memory T cell homing to the skin may provide promising targets for the development of novel therapeutics. Here results of recent studies associating chemokines with a psoriatic phenotype and delineating their role in the recruitment of memory T cells to the skin are discussed.
Keywords: chemokines, chemokine receptors, psoriasis, therapy, ccr4, ccr6, cccr10, cxcr3
Current Drug Targets - Inflammation & Allergy
Title: Chemokines and Chemokine Receptors as Targets in the Therapy of Psoriasis
Volume: 3 Issue: 2
Author(s): Bernhard Homey
Affiliation:
Keywords: chemokines, chemokine receptors, psoriasis, therapy, ccr4, ccr6, cccr10, cxcr3
Abstract: Chemokines are members of a superfamily of small, cytokine-like, chemotactic proteins that have recently been shown to critically regulate leukocyte trafficking. Accumulating evidence indicates that the chronically relapsing inflammatory skin disease psoriasis represents a T cell-mediated disease. Thus, the understanding of the underlying mechanisms of memory T cell homing to the skin may provide promising targets for the development of novel therapeutics. Here results of recent studies associating chemokines with a psoriatic phenotype and delineating their role in the recruitment of memory T cells to the skin are discussed.
Export Options
About this article
Cite this article as:
Homey Bernhard, Chemokines and Chemokine Receptors as Targets in the Therapy of Psoriasis, Current Drug Targets - Inflammation & Allergy 2004; 3 (2) . https://dx.doi.org/10.2174/1568010043343840
DOI https://dx.doi.org/10.2174/1568010043343840 |
Print ISSN 1568-010X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-010X |
Related Articles
-
Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Cardiovascular Drug Discovery The Development of HEPT-Type HIV Non-Nucleoside Reverse Transcriptase Inhibitors and Its Implications for DABO Family
Current Pharmaceutical Design Cytogenetic and Molecular Abnormalities in Myelodysplastic Syndrome
Current Molecular Medicine Endogenous Inhibitors of HIV: Potent Anti-HIV Activity of Leukemia Inhibitory Factor
Current Molecular Medicine Current and Under Development Treatment Modalities of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Family of Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Acetyl-L-Carnitine Modulates TP53 and IL10 Gene Expression Induced by 3-NPA Evoked Toxicity in PC12 Cells
Current Neuropharmacology Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Products Combating Neurodegeneration: Parkinson’s Disease
Current Drug Metabolism LYP3, a New Bestatin Derivative for Aminopeptidase N Inhibition
Medicinal Chemistry Part I: Targeted Particles for Cancer Immunotherapy
Current Drug Delivery CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry The Utility of Antiemetics in the Prevention and Treatment of Postoperative Nausea and Vomiting in Patients Scheduled for Laparoscopic Cholecystectomy
Current Pharmaceutical Design Circulating Levels of Uric Acid and Risk for Metabolic Syndrome
Current Diabetes Reviews The Role of Transforming Growth Factor-β in Cardiac Fibrosis
Current Enzyme Inhibition New Drugs for Immune Targeting
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets